10
Participants
Start Date
April 15, 2022
Primary Completion Date
May 28, 2025
Study Completion Date
May 28, 2025
VOR33
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
National Institutes of Health, Clinical Center, Bethesda
Miami Cancer Institute, Miami
University Hospitals Seidman Cancer Center, Cleveland
Washington University School of Medicine Siteman Cancer Center, St Louis
University of California San Diego Moores Cancer Center, La Jolla
Fred Hutchinson Cancer Research Center, Seattle
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Hôpital Maisonneuve-Rosemont, Montreal
Lead Sponsor
Vor Biopharma
INDUSTRY